The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading ->
Incarcerated people suffer from poorer health outcomes and limited access to health care, which can impact them and their communities even after release. However, prisoners’ health is not being monitored well, and there is a lack of evidence to inform policy making to improve the health of prison populations. These are the main findings of […] Continue reading ->
Italy’s former Undersecretary of State for Health, Armando Bartolazzi, discusses the implications of recent moves to replace the head of the Italian Medicines Agency (AIFA), based on political considerations of the a new Health Minister.   “Health is a Political Choice” said WHO Director-General Dr Tedros in his keynote session at the World Health Summit, […] Continue reading ->
In a move fraught with international political overtones, Italy’s new Minister of Health is moving to replace the Director General of the Italian Drug Agency (AIFA), Dr Luca Li Bassi, who was the key architect of the May World Health Assembly (WHA) resolution supporting greater price transparency in medicines markets, Health Policy Watch has learned. […] Continue reading ->
Bad Hofgastein, Austria – A call to action to make stronger individual and collective commitments for climate change and health marked the end of the European Health Forum (Gastein). The closing plenary session, titled “the global climate crisis: a public health emergency,” ended the varied program with discussions on two issues high on the political […] Continue reading ->